Representative Glenn Grothman Addresses Oral Chemotherapy Affordability in House Oversight Hearing
Representative Glenn Grothman, serving as Chairman of the House Oversight Subcommittee on Health Care and Financial Services, led a hearing on September 15, 2026, titled 'Unequal Treatment: Addressing the Drivers of Unaffordability for Oral Chemotherapy.' The hearing focused on the disparity in out-of-pocket costs for oral versus intravenous chemotherapy treatments. Chairman Grothman's opening remarks highlighted the significant role of insurers and pharmacy benefit managers (PBMs) in the oral-drug supply chain. He argued that current benefit designs, pharmacy networks, and utilization-management rules often lead to high out-of-pocket costs and treatment delays for patients. The witness panel, comprising representatives from oncology practices, academic cancer care, and patient advocacy, discussed the financial and administrative hurdles patients face in accessing oral cancer medicines. The discussion explored how pharmacy-benefit coverage can differ from medical-benefit coverage for infused drugs, and how...